Abstract
<jats:p>Interventional treatment remains one of the most effective methods of rhythm control in most patients with atrial fibrillation (AF). The development of innovative methods and the introduction of novel technologies in modern arrhythmology are expanding the potential for maintaining a stable sinus rhythm, reducing the risk of thromboembolic complications, and improving patients’ quality of life. In addition to traditional electrical cardioversion, drug-based approaches, including the use of Russian-made antiarrhythmic agents, are increasingly being used when performing intraoperative cardioversion in patients with AF. This paper presents experience with the use of Refralon (cavutilide) for pharmacological cardioversion in the acute phase of radiofrequency pulmonary vein isolation in patients with various AF forms.</jats:p>